nodes	percent_of_prediction	percent_of_DWPC	metapath
Naproxen—PTGS2—thyroid cancer	0.306	1	CbGaD
Naproxen—AKR1C3—Doxorubicin—thyroid cancer	0.178	0.38	CbGbCtD
Naproxen—UGT2B7—Epirubicin—thyroid cancer	0.104	0.223	CbGbCtD
Naproxen—UGT1A1—Sorafenib—thyroid cancer	0.0791	0.169	CbGbCtD
Naproxen—ALB—Vandetanib—thyroid cancer	0.0497	0.106	CbGbCtD
Naproxen—CYP2C8—Sorafenib—thyroid cancer	0.0232	0.0495	CbGbCtD
Naproxen—CYP1A2—Sorafenib—thyroid cancer	0.0179	0.0383	CbGbCtD
Naproxen—CYP2C9—Sorafenib—thyroid cancer	0.0162	0.0345	CbGbCtD
Naproxen—Nabumetone—PTGS2—thyroid cancer	0.000697	0.168	CrCbGaD
Naproxen—Carprofen—PTGS2—thyroid cancer	0.000665	0.161	CrCbGaD
Naproxen—Indomethacin—PPARG—thyroid cancer	0.000619	0.149	CrCbGaD
Naproxen—Ibuprofen—PPARG—thyroid cancer	0.000487	0.118	CrCbGaD
Naproxen—Suprofen—PTGS2—thyroid cancer	0.000411	0.0992	CrCbGaD
Naproxen—Fenoprofen—PTGS2—thyroid cancer	0.000354	0.0855	CrCbGaD
Naproxen—Indomethacin—PTGS2—thyroid cancer	0.000261	0.0631	CrCbGaD
Naproxen—Flurbiprofen—PTGS2—thyroid cancer	0.000231	0.0558	CrCbGaD
Naproxen—Ketoprofen—PTGS2—thyroid cancer	0.000209	0.0505	CrCbGaD
Naproxen—Ibuprofen—PTGS2—thyroid cancer	0.000206	0.0497	CrCbGaD
Naproxen—Migraine—Doxorubicin—thyroid cancer	0.000135	0.000784	CcSEcCtD
Naproxen—Hypokalaemia—Epirubicin—thyroid cancer	0.000135	0.000784	CcSEcCtD
Naproxen—Diarrhoea—Sorafenib—thyroid cancer	0.000135	0.000783	CcSEcCtD
Naproxen—Breast disorder—Epirubicin—thyroid cancer	0.000134	0.000778	CcSEcCtD
Naproxen—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.000134	0.000775	CcSEcCtD
Naproxen—Gastritis—Epirubicin—thyroid cancer	0.000131	0.000762	CcSEcCtD
Naproxen—Muscular weakness—Epirubicin—thyroid cancer	0.000131	0.000759	CcSEcCtD
Naproxen—Dizziness—Sorafenib—thyroid cancer	0.000131	0.000757	CcSEcCtD
Naproxen—Mood swings—Doxorubicin—thyroid cancer	0.00013	0.000755	CcSEcCtD
Naproxen—Abdominal distension—Epirubicin—thyroid cancer	0.000129	0.000749	CcSEcCtD
Naproxen—Blood creatinine increased—Doxorubicin—thyroid cancer	0.000129	0.000746	CcSEcCtD
Naproxen—Influenza—Epirubicin—thyroid cancer	0.000128	0.000744	CcSEcCtD
Naproxen—Asthma—Epirubicin—thyroid cancer	0.000128	0.000744	CcSEcCtD
Naproxen—Dysphagia—Epirubicin—thyroid cancer	0.000128	0.000744	CcSEcCtD
Naproxen—Dehydration—Doxorubicin—thyroid cancer	0.000128	0.000741	CcSEcCtD
Naproxen—Eosinophilia—Epirubicin—thyroid cancer	0.000127	0.000737	CcSEcCtD
Naproxen—Liver function test abnormal—Doxorubicin—thyroid cancer	0.000127	0.000736	CcSEcCtD
Naproxen—Dry skin—Doxorubicin—thyroid cancer	0.000126	0.00073	CcSEcCtD
Naproxen—Pancreatitis—Epirubicin—thyroid cancer	0.000126	0.00073	CcSEcCtD
Naproxen—Vomiting—Sorafenib—thyroid cancer	0.000126	0.000728	CcSEcCtD
Naproxen—Abdominal pain upper—Doxorubicin—thyroid cancer	0.000126	0.000728	CcSEcCtD
Naproxen—Hypokalaemia—Doxorubicin—thyroid cancer	0.000125	0.000725	CcSEcCtD
Naproxen—Angina pectoris—Epirubicin—thyroid cancer	0.000125	0.000725	CcSEcCtD
Naproxen—Rash—Sorafenib—thyroid cancer	0.000125	0.000722	CcSEcCtD
Naproxen—Dermatitis—Sorafenib—thyroid cancer	0.000124	0.000721	CcSEcCtD
Naproxen—Breast disorder—Doxorubicin—thyroid cancer	0.000124	0.00072	CcSEcCtD
Naproxen—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.000124	0.000717	CcSEcCtD
Naproxen—Headache—Sorafenib—thyroid cancer	0.000124	0.000717	CcSEcCtD
Naproxen—Bronchitis—Epirubicin—thyroid cancer	0.000123	0.000716	CcSEcCtD
Naproxen—Pancytopenia—Epirubicin—thyroid cancer	0.000122	0.000707	CcSEcCtD
Naproxen—Gastritis—Doxorubicin—thyroid cancer	0.000122	0.000705	CcSEcCtD
Naproxen—Muscular weakness—Doxorubicin—thyroid cancer	0.000121	0.000703	CcSEcCtD
Naproxen—Dysuria—Epirubicin—thyroid cancer	0.00012	0.000696	CcSEcCtD
Naproxen—Abdominal distension—Doxorubicin—thyroid cancer	0.00012	0.000693	CcSEcCtD
Naproxen—Influenza—Doxorubicin—thyroid cancer	0.000119	0.000689	CcSEcCtD
Naproxen—Asthma—Doxorubicin—thyroid cancer	0.000119	0.000689	CcSEcCtD
Naproxen—Dysphagia—Doxorubicin—thyroid cancer	0.000119	0.000689	CcSEcCtD
Naproxen—Pollakiuria—Epirubicin—thyroid cancer	0.000119	0.000687	CcSEcCtD
Naproxen—Eosinophilia—Doxorubicin—thyroid cancer	0.000118	0.000682	CcSEcCtD
Naproxen—Nausea—Sorafenib—thyroid cancer	0.000117	0.00068	CcSEcCtD
Naproxen—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000117	0.000679	CcSEcCtD
Naproxen—Pancreatitis—Doxorubicin—thyroid cancer	0.000116	0.000675	CcSEcCtD
Naproxen—Weight decreased—Epirubicin—thyroid cancer	0.000116	0.000673	CcSEcCtD
Naproxen—Hyperglycaemia—Epirubicin—thyroid cancer	0.000116	0.000671	CcSEcCtD
Naproxen—Angina pectoris—Doxorubicin—thyroid cancer	0.000116	0.000671	CcSEcCtD
Naproxen—Pneumonia—Epirubicin—thyroid cancer	0.000115	0.000667	CcSEcCtD
Naproxen—Drowsiness—Epirubicin—thyroid cancer	0.000114	0.000664	CcSEcCtD
Naproxen—Bronchitis—Doxorubicin—thyroid cancer	0.000114	0.000662	CcSEcCtD
Naproxen—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000114	0.000658	CcSEcCtD
Naproxen—Pancytopenia—Doxorubicin—thyroid cancer	0.000113	0.000654	CcSEcCtD
Naproxen—Renal failure—Epirubicin—thyroid cancer	0.000113	0.000652	CcSEcCtD
Naproxen—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000112	0.00065	CcSEcCtD
Naproxen—Stomatitis—Epirubicin—thyroid cancer	0.000112	0.000647	CcSEcCtD
Naproxen—Jaundice—Epirubicin—thyroid cancer	0.000112	0.000647	CcSEcCtD
Naproxen—Urinary tract infection—Epirubicin—thyroid cancer	0.000111	0.000645	CcSEcCtD
Naproxen—Conjunctivitis—Epirubicin—thyroid cancer	0.000111	0.000645	CcSEcCtD
Naproxen—Dysuria—Doxorubicin—thyroid cancer	0.000111	0.000644	CcSEcCtD
Naproxen—Sweating—Epirubicin—thyroid cancer	0.00011	0.000636	CcSEcCtD
Naproxen—Pollakiuria—Doxorubicin—thyroid cancer	0.00011	0.000636	CcSEcCtD
Naproxen—Haematuria—Epirubicin—thyroid cancer	0.000109	0.000633	CcSEcCtD
Naproxen—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000108	0.000629	CcSEcCtD
Naproxen—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000108	0.000628	CcSEcCtD
Naproxen—Epistaxis—Epirubicin—thyroid cancer	0.000108	0.000626	CcSEcCtD
Naproxen—Weight decreased—Doxorubicin—thyroid cancer	0.000107	0.000623	CcSEcCtD
Naproxen—Sinusitis—Epirubicin—thyroid cancer	0.000107	0.000623	CcSEcCtD
Naproxen—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000107	0.000621	CcSEcCtD
Naproxen—Agranulocytosis—Epirubicin—thyroid cancer	0.000107	0.000619	CcSEcCtD
Naproxen—Pneumonia—Doxorubicin—thyroid cancer	0.000107	0.000618	CcSEcCtD
Naproxen—Drowsiness—Doxorubicin—thyroid cancer	0.000106	0.000614	CcSEcCtD
Naproxen—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000105	0.000609	CcSEcCtD
Naproxen—Renal failure—Doxorubicin—thyroid cancer	0.000104	0.000604	CcSEcCtD
Naproxen—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000104	0.000602	CcSEcCtD
Naproxen—Haemoglobin—Epirubicin—thyroid cancer	0.000103	0.000599	CcSEcCtD
Naproxen—Stomatitis—Doxorubicin—thyroid cancer	0.000103	0.000598	CcSEcCtD
Naproxen—Jaundice—Doxorubicin—thyroid cancer	0.000103	0.000598	CcSEcCtD
Naproxen—Rhinitis—Epirubicin—thyroid cancer	0.000103	0.000597	CcSEcCtD
Naproxen—Conjunctivitis—Doxorubicin—thyroid cancer	0.000103	0.000597	CcSEcCtD
Naproxen—Urinary tract infection—Doxorubicin—thyroid cancer	0.000103	0.000597	CcSEcCtD
Naproxen—Haemorrhage—Epirubicin—thyroid cancer	0.000103	0.000596	CcSEcCtD
Naproxen—Hepatitis—Epirubicin—thyroid cancer	0.000103	0.000596	CcSEcCtD
Naproxen—Pharyngitis—Epirubicin—thyroid cancer	0.000102	0.000591	CcSEcCtD
Naproxen—Sweating—Doxorubicin—thyroid cancer	0.000102	0.000589	CcSEcCtD
Naproxen—Urinary tract disorder—Epirubicin—thyroid cancer	0.000102	0.000588	CcSEcCtD
Naproxen—Oedema peripheral—Epirubicin—thyroid cancer	0.000101	0.000587	CcSEcCtD
Naproxen—Haematuria—Doxorubicin—thyroid cancer	0.000101	0.000585	CcSEcCtD
Naproxen—Connective tissue disorder—Epirubicin—thyroid cancer	0.000101	0.000585	CcSEcCtD
Naproxen—Urethral disorder—Epirubicin—thyroid cancer	0.000101	0.000584	CcSEcCtD
Naproxen—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.0001	0.000581	CcSEcCtD
Naproxen—Epistaxis—Doxorubicin—thyroid cancer	9.99e-05	0.000579	CcSEcCtD
Naproxen—Sinusitis—Doxorubicin—thyroid cancer	9.94e-05	0.000576	CcSEcCtD
Naproxen—Visual impairment—Epirubicin—thyroid cancer	9.91e-05	0.000574	CcSEcCtD
Naproxen—Agranulocytosis—Doxorubicin—thyroid cancer	9.89e-05	0.000573	CcSEcCtD
Naproxen—Erythema multiforme—Epirubicin—thyroid cancer	9.72e-05	0.000563	CcSEcCtD
Naproxen—Eye disorder—Epirubicin—thyroid cancer	9.61e-05	0.000557	CcSEcCtD
Naproxen—Tinnitus—Epirubicin—thyroid cancer	9.58e-05	0.000555	CcSEcCtD
Naproxen—Haemoglobin—Doxorubicin—thyroid cancer	9.56e-05	0.000554	CcSEcCtD
Naproxen—Cardiac disorder—Epirubicin—thyroid cancer	9.54e-05	0.000553	CcSEcCtD
Naproxen—Rhinitis—Doxorubicin—thyroid cancer	9.53e-05	0.000553	CcSEcCtD
Naproxen—Hepatitis—Doxorubicin—thyroid cancer	9.51e-05	0.000551	CcSEcCtD
Naproxen—Haemorrhage—Doxorubicin—thyroid cancer	9.51e-05	0.000551	CcSEcCtD
Naproxen—Pharyngitis—Doxorubicin—thyroid cancer	9.44e-05	0.000547	CcSEcCtD
Naproxen—Urinary tract disorder—Doxorubicin—thyroid cancer	9.39e-05	0.000544	CcSEcCtD
Naproxen—Oedema peripheral—Doxorubicin—thyroid cancer	9.37e-05	0.000543	CcSEcCtD
Naproxen—Connective tissue disorder—Doxorubicin—thyroid cancer	9.35e-05	0.000542	CcSEcCtD
Naproxen—Angiopathy—Epirubicin—thyroid cancer	9.33e-05	0.00054	CcSEcCtD
Naproxen—Urethral disorder—Doxorubicin—thyroid cancer	9.32e-05	0.00054	CcSEcCtD
Naproxen—Immune system disorder—Epirubicin—thyroid cancer	9.28e-05	0.000538	CcSEcCtD
Naproxen—Mediastinal disorder—Epirubicin—thyroid cancer	9.26e-05	0.000537	CcSEcCtD
Naproxen—Chills—Epirubicin—thyroid cancer	9.22e-05	0.000534	CcSEcCtD
Naproxen—Arrhythmia—Epirubicin—thyroid cancer	9.18e-05	0.000532	CcSEcCtD
Naproxen—Visual impairment—Doxorubicin—thyroid cancer	9.17e-05	0.000531	CcSEcCtD
Naproxen—Alopecia—Epirubicin—thyroid cancer	9.08e-05	0.000526	CcSEcCtD
Naproxen—Mental disorder—Epirubicin—thyroid cancer	9e-05	0.000522	CcSEcCtD
Naproxen—Erythema multiforme—Doxorubicin—thyroid cancer	8.99e-05	0.000521	CcSEcCtD
Naproxen—Malnutrition—Epirubicin—thyroid cancer	8.95e-05	0.000519	CcSEcCtD
Naproxen—Erythema—Epirubicin—thyroid cancer	8.95e-05	0.000519	CcSEcCtD
Naproxen—Eye disorder—Doxorubicin—thyroid cancer	8.89e-05	0.000515	CcSEcCtD
Naproxen—Tinnitus—Doxorubicin—thyroid cancer	8.87e-05	0.000514	CcSEcCtD
Naproxen—Cardiac disorder—Doxorubicin—thyroid cancer	8.83e-05	0.000512	CcSEcCtD
Naproxen—Flatulence—Epirubicin—thyroid cancer	8.82e-05	0.000511	CcSEcCtD
Naproxen—Tension—Epirubicin—thyroid cancer	8.78e-05	0.000509	CcSEcCtD
Naproxen—Nervousness—Epirubicin—thyroid cancer	8.69e-05	0.000504	CcSEcCtD
Naproxen—Angiopathy—Doxorubicin—thyroid cancer	8.63e-05	0.0005	CcSEcCtD
Naproxen—Muscle spasms—Epirubicin—thyroid cancer	8.6e-05	0.000499	CcSEcCtD
Naproxen—Immune system disorder—Doxorubicin—thyroid cancer	8.59e-05	0.000498	CcSEcCtD
Naproxen—Mediastinal disorder—Doxorubicin—thyroid cancer	8.57e-05	0.000497	CcSEcCtD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	8.54e-05	0.00175	CbGpPWpGaD
Naproxen—Chills—Doxorubicin—thyroid cancer	8.53e-05	0.000495	CcSEcCtD
Naproxen—Arrhythmia—Doxorubicin—thyroid cancer	8.5e-05	0.000492	CcSEcCtD
Naproxen—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—thyroid cancer	8.49e-05	0.00174	CbGpPWpGaD
Naproxen—Vision blurred—Epirubicin—thyroid cancer	8.43e-05	0.000489	CcSEcCtD
Naproxen—Alopecia—Doxorubicin—thyroid cancer	8.4e-05	0.000487	CcSEcCtD
Naproxen—Mental disorder—Doxorubicin—thyroid cancer	8.33e-05	0.000483	CcSEcCtD
Naproxen—SLCO1A2—Metabolism—NDUFA13—thyroid cancer	8.31e-05	0.00171	CbGpPWpGaD
Naproxen—Ill-defined disorder—Epirubicin—thyroid cancer	8.3e-05	0.000481	CcSEcCtD
Naproxen—Erythema—Doxorubicin—thyroid cancer	8.28e-05	0.00048	CcSEcCtD
Naproxen—Malnutrition—Doxorubicin—thyroid cancer	8.28e-05	0.00048	CcSEcCtD
Naproxen—Anaemia—Epirubicin—thyroid cancer	8.27e-05	0.000479	CcSEcCtD
Naproxen—Flatulence—Doxorubicin—thyroid cancer	8.16e-05	0.000473	CcSEcCtD
Naproxen—Tension—Doxorubicin—thyroid cancer	8.12e-05	0.000471	CcSEcCtD
Naproxen—Malaise—Epirubicin—thyroid cancer	8.07e-05	0.000468	CcSEcCtD
Naproxen—Nervousness—Doxorubicin—thyroid cancer	8.04e-05	0.000466	CcSEcCtD
Naproxen—Vertigo—Epirubicin—thyroid cancer	8.04e-05	0.000466	CcSEcCtD
Naproxen—Syncope—Epirubicin—thyroid cancer	8.02e-05	0.000465	CcSEcCtD
Naproxen—Leukopenia—Epirubicin—thyroid cancer	8.01e-05	0.000464	CcSEcCtD
Naproxen—Muscle spasms—Doxorubicin—thyroid cancer	7.96e-05	0.000461	CcSEcCtD
Naproxen—Palpitations—Epirubicin—thyroid cancer	7.91e-05	0.000458	CcSEcCtD
Naproxen—Loss of consciousness—Epirubicin—thyroid cancer	7.86e-05	0.000456	CcSEcCtD
Naproxen—SLCO1A2—Metabolism—CHST14—thyroid cancer	7.81e-05	0.0016	CbGpPWpGaD
Naproxen—Cough—Epirubicin—thyroid cancer	7.81e-05	0.000452	CcSEcCtD
Naproxen—Vision blurred—Doxorubicin—thyroid cancer	7.8e-05	0.000452	CcSEcCtD
Naproxen—Convulsion—Epirubicin—thyroid cancer	7.75e-05	0.000449	CcSEcCtD
Naproxen—UGT1A1—Metabolism—NDUFA13—thyroid cancer	7.75e-05	0.00159	CbGpPWpGaD
Naproxen—Hypertension—Epirubicin—thyroid cancer	7.73e-05	0.000448	CcSEcCtD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—TPR—thyroid cancer	7.72e-05	0.00159	CbGpPWpGaD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—CP—thyroid cancer	7.72e-05	0.00159	CbGpPWpGaD
Naproxen—Ill-defined disorder—Doxorubicin—thyroid cancer	7.68e-05	0.000445	CcSEcCtD
Naproxen—PTGS2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	7.67e-05	0.00158	CbGpPWpGaD
Naproxen—Anaemia—Doxorubicin—thyroid cancer	7.65e-05	0.000443	CcSEcCtD
Naproxen—Arthralgia—Epirubicin—thyroid cancer	7.62e-05	0.000441	CcSEcCtD
Naproxen—Chest pain—Epirubicin—thyroid cancer	7.62e-05	0.000441	CcSEcCtD
Naproxen—Myalgia—Epirubicin—thyroid cancer	7.62e-05	0.000441	CcSEcCtD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	7.59e-05	0.00156	CbGpPWpGaD
Naproxen—Anxiety—Epirubicin—thyroid cancer	7.59e-05	0.00044	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	7.57e-05	0.000438	CcSEcCtD
Naproxen—AKR1C3—Disease—TPR—thyroid cancer	7.55e-05	0.00155	CbGpPWpGaD
Naproxen—Discomfort—Epirubicin—thyroid cancer	7.53e-05	0.000436	CcSEcCtD
Naproxen—Malaise—Doxorubicin—thyroid cancer	7.47e-05	0.000433	CcSEcCtD
Naproxen—Dry mouth—Epirubicin—thyroid cancer	7.45e-05	0.000432	CcSEcCtD
Naproxen—Vertigo—Doxorubicin—thyroid cancer	7.44e-05	0.000431	CcSEcCtD
Naproxen—PTGS1—Metabolism—MINPP1—thyroid cancer	7.43e-05	0.00153	CbGpPWpGaD
Naproxen—Syncope—Doxorubicin—thyroid cancer	7.42e-05	0.00043	CcSEcCtD
Naproxen—AKR1C3—Disease—PRKAR1A—thyroid cancer	7.42e-05	0.00152	CbGpPWpGaD
Naproxen—ALB—SLC-mediated transmembrane transport—TPR—thyroid cancer	7.42e-05	0.00152	CbGpPWpGaD
Naproxen—ALB—SLC-mediated transmembrane transport—CP—thyroid cancer	7.42e-05	0.00152	CbGpPWpGaD
Naproxen—Leukopenia—Doxorubicin—thyroid cancer	7.41e-05	0.000429	CcSEcCtD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	7.39e-05	0.00152	CbGpPWpGaD
Naproxen—Confusional state—Epirubicin—thyroid cancer	7.36e-05	0.000427	CcSEcCtD
Naproxen—Palpitations—Doxorubicin—thyroid cancer	7.32e-05	0.000424	CcSEcCtD
Naproxen—Anaphylactic shock—Epirubicin—thyroid cancer	7.3e-05	0.000423	CcSEcCtD
Naproxen—Oedema—Epirubicin—thyroid cancer	7.3e-05	0.000423	CcSEcCtD
Naproxen—UGT1A1—Metabolism—CHST14—thyroid cancer	7.29e-05	0.0015	CbGpPWpGaD
Naproxen—Loss of consciousness—Doxorubicin—thyroid cancer	7.28e-05	0.000422	CcSEcCtD
Naproxen—SLC22A6—Transmembrane transport of small molecules—CP—thyroid cancer	7.26e-05	0.00149	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—TPR—thyroid cancer	7.26e-05	0.00149	CbGpPWpGaD
Naproxen—Infection—Epirubicin—thyroid cancer	7.25e-05	0.00042	CcSEcCtD
Naproxen—UGT2B7—Metabolism—HPGD—thyroid cancer	7.23e-05	0.00148	CbGpPWpGaD
Naproxen—Cough—Doxorubicin—thyroid cancer	7.22e-05	0.000419	CcSEcCtD
Naproxen—AKR1C3—Signaling Pathways—TCF7L1—thyroid cancer	7.22e-05	0.00148	CbGpPWpGaD
Naproxen—Shock—Epirubicin—thyroid cancer	7.18e-05	0.000416	CcSEcCtD
Naproxen—Convulsion—Doxorubicin—thyroid cancer	7.17e-05	0.000416	CcSEcCtD
Naproxen—Nervous system disorder—Epirubicin—thyroid cancer	7.16e-05	0.000415	CcSEcCtD
Naproxen—Thrombocytopenia—Epirubicin—thyroid cancer	7.15e-05	0.000414	CcSEcCtD
Naproxen—Hypertension—Doxorubicin—thyroid cancer	7.15e-05	0.000414	CcSEcCtD
Naproxen—SLC22A6—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	7.14e-05	0.00147	CbGpPWpGaD
Naproxen—Tachycardia—Epirubicin—thyroid cancer	7.13e-05	0.000413	CcSEcCtD
Naproxen—CYP2C9—Arachidonic acid metabolism—PTGS2—thyroid cancer	7.1e-05	0.00146	CbGpPWpGaD
Naproxen—AKR1C3—Disease—MEN1—thyroid cancer	7.09e-05	0.00146	CbGpPWpGaD
Naproxen—Skin disorder—Epirubicin—thyroid cancer	7.09e-05	0.000411	CcSEcCtD
Naproxen—Hyperhidrosis—Epirubicin—thyroid cancer	7.06e-05	0.000409	CcSEcCtD
Naproxen—Myalgia—Doxorubicin—thyroid cancer	7.05e-05	0.000408	CcSEcCtD
Naproxen—Arthralgia—Doxorubicin—thyroid cancer	7.05e-05	0.000408	CcSEcCtD
Naproxen—Chest pain—Doxorubicin—thyroid cancer	7.05e-05	0.000408	CcSEcCtD
Naproxen—Anxiety—Doxorubicin—thyroid cancer	7.02e-05	0.000407	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	7e-05	0.000406	CcSEcCtD
Naproxen—Discomfort—Doxorubicin—thyroid cancer	6.96e-05	0.000404	CcSEcCtD
Naproxen—Anorexia—Epirubicin—thyroid cancer	6.96e-05	0.000403	CcSEcCtD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	6.95e-05	0.00143	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	6.91e-05	0.00142	CbGpPWpGaD
Naproxen—Dry mouth—Doxorubicin—thyroid cancer	6.89e-05	0.000399	CcSEcCtD
Naproxen—Hypotension—Epirubicin—thyroid cancer	6.82e-05	0.000395	CcSEcCtD
Naproxen—Confusional state—Doxorubicin—thyroid cancer	6.81e-05	0.000395	CcSEcCtD
Naproxen—Oedema—Doxorubicin—thyroid cancer	6.76e-05	0.000392	CcSEcCtD
Naproxen—Anaphylactic shock—Doxorubicin—thyroid cancer	6.76e-05	0.000392	CcSEcCtD
Naproxen—Infection—Doxorubicin—thyroid cancer	6.71e-05	0.000389	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Epirubicin—thyroid cancer	6.65e-05	0.000386	CcSEcCtD
Naproxen—Shock—Doxorubicin—thyroid cancer	6.65e-05	0.000385	CcSEcCtD
Naproxen—Nervous system disorder—Doxorubicin—thyroid cancer	6.63e-05	0.000384	CcSEcCtD
Naproxen—Thrombocytopenia—Doxorubicin—thyroid cancer	6.62e-05	0.000383	CcSEcCtD
Naproxen—Insomnia—Epirubicin—thyroid cancer	6.6e-05	0.000383	CcSEcCtD
Naproxen—Tachycardia—Doxorubicin—thyroid cancer	6.59e-05	0.000382	CcSEcCtD
Naproxen—Skin disorder—Doxorubicin—thyroid cancer	6.56e-05	0.00038	CcSEcCtD
Naproxen—Paraesthesia—Epirubicin—thyroid cancer	6.56e-05	0.00038	CcSEcCtD
Naproxen—CYP2C8—Biological oxidations—RXRA—thyroid cancer	6.53e-05	0.00134	CbGpPWpGaD
Naproxen—Hyperhidrosis—Doxorubicin—thyroid cancer	6.53e-05	0.000379	CcSEcCtD
Naproxen—PTGS2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	6.52e-05	0.00134	CbGpPWpGaD
Naproxen—Dyspnoea—Epirubicin—thyroid cancer	6.51e-05	0.000377	CcSEcCtD
Naproxen—Somnolence—Epirubicin—thyroid cancer	6.49e-05	0.000376	CcSEcCtD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	6.48e-05	0.00133	CbGpPWpGaD
Naproxen—Anorexia—Doxorubicin—thyroid cancer	6.44e-05	0.000373	CcSEcCtD
Naproxen—Dyspepsia—Epirubicin—thyroid cancer	6.43e-05	0.000373	CcSEcCtD
Naproxen—PTGS2—C-MYB transcription factor network—CCND1—thyroid cancer	6.39e-05	0.00131	CbGpPWpGaD
Naproxen—Decreased appetite—Epirubicin—thyroid cancer	6.35e-05	0.000368	CcSEcCtD
Naproxen—AKR1C3—Metabolism—TPR—thyroid cancer	6.32e-05	0.0013	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—NDUFA13—thyroid cancer	6.32e-05	0.0013	CbGpPWpGaD
Naproxen—Hypotension—Doxorubicin—thyroid cancer	6.31e-05	0.000366	CcSEcCtD
Naproxen—Gastrointestinal disorder—Epirubicin—thyroid cancer	6.3e-05	0.000365	CcSEcCtD
Naproxen—Fatigue—Epirubicin—thyroid cancer	6.3e-05	0.000365	CcSEcCtD
Naproxen—SLCO1A2—Metabolism—HPGD—thyroid cancer	6.3e-05	0.00129	CbGpPWpGaD
Naproxen—Pain—Epirubicin—thyroid cancer	6.24e-05	0.000362	CcSEcCtD
Naproxen—Constipation—Epirubicin—thyroid cancer	6.24e-05	0.000362	CcSEcCtD
Naproxen—AKR1C3—Metabolism—PRKAR1A—thyroid cancer	6.22e-05	0.00128	CbGpPWpGaD
Naproxen—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	6.16e-05	0.000357	CcSEcCtD
Naproxen—Insomnia—Doxorubicin—thyroid cancer	6.11e-05	0.000354	CcSEcCtD
Naproxen—Paraesthesia—Doxorubicin—thyroid cancer	6.07e-05	0.000352	CcSEcCtD
Naproxen—CYP1A2—Arachidonic acid metabolism—PTGS2—thyroid cancer	6.06e-05	0.00125	CbGpPWpGaD
Naproxen—Dyspnoea—Doxorubicin—thyroid cancer	6.02e-05	0.000349	CcSEcCtD
Naproxen—Feeling abnormal—Epirubicin—thyroid cancer	6.02e-05	0.000349	CcSEcCtD
Naproxen—Somnolence—Doxorubicin—thyroid cancer	6.01e-05	0.000348	CcSEcCtD
Naproxen—PTGS2—Disease—TRIM24—thyroid cancer	5.99e-05	0.00123	CbGpPWpGaD
Naproxen—Gastrointestinal pain—Epirubicin—thyroid cancer	5.97e-05	0.000346	CcSEcCtD
Naproxen—Dyspepsia—Doxorubicin—thyroid cancer	5.95e-05	0.000345	CcSEcCtD
Naproxen—PTGS1—Metabolism—CHST14—thyroid cancer	5.94e-05	0.00122	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—MINPP1—thyroid cancer	5.9e-05	0.00121	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—HPGD—thyroid cancer	5.87e-05	0.00121	CbGpPWpGaD
Naproxen—Decreased appetite—Doxorubicin—thyroid cancer	5.87e-05	0.00034	CcSEcCtD
Naproxen—Gastrointestinal disorder—Doxorubicin—thyroid cancer	5.83e-05	0.000338	CcSEcCtD
Naproxen—Fatigue—Doxorubicin—thyroid cancer	5.83e-05	0.000338	CcSEcCtD
Naproxen—Urticaria—Epirubicin—thyroid cancer	5.8e-05	0.000336	CcSEcCtD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	5.78e-05	0.00119	CbGpPWpGaD
Naproxen—Constipation—Doxorubicin—thyroid cancer	5.78e-05	0.000335	CcSEcCtD
Naproxen—Pain—Doxorubicin—thyroid cancer	5.78e-05	0.000335	CcSEcCtD
Naproxen—Body temperature increased—Epirubicin—thyroid cancer	5.77e-05	0.000335	CcSEcCtD
Naproxen—Abdominal pain—Epirubicin—thyroid cancer	5.77e-05	0.000335	CcSEcCtD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	5.65e-05	0.00116	CbGpPWpGaD
Naproxen—AKR1C3—Disease—CALCA—thyroid cancer	5.65e-05	0.00116	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	5.63e-05	0.00116	CbGpPWpGaD
Naproxen—PTGS2—Disease—CHST14—thyroid cancer	5.63e-05	0.00116	CbGpPWpGaD
Naproxen—Feeling abnormal—Doxorubicin—thyroid cancer	5.57e-05	0.000323	CcSEcCtD
Naproxen—ALB—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	5.56e-05	0.00114	CbGpPWpGaD
Naproxen—Gastrointestinal pain—Doxorubicin—thyroid cancer	5.53e-05	0.00032	CcSEcCtD
Naproxen—ALB—Selenium Micronutrient Network—PTGS2—thyroid cancer	5.52e-05	0.00113	CbGpPWpGaD
Naproxen—PTGS2—C-MYB transcription factor network—NRAS—thyroid cancer	5.51e-05	0.00113	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	5.43e-05	0.00112	CbGpPWpGaD
Naproxen—Hypersensitivity—Epirubicin—thyroid cancer	5.38e-05	0.000312	CcSEcCtD
Naproxen—Urticaria—Doxorubicin—thyroid cancer	5.37e-05	0.000311	CcSEcCtD
Naproxen—Abdominal pain—Doxorubicin—thyroid cancer	5.34e-05	0.00031	CcSEcCtD
Naproxen—Body temperature increased—Doxorubicin—thyroid cancer	5.34e-05	0.00031	CcSEcCtD
Naproxen—PTGS2—Disease—TRIM33—thyroid cancer	5.34e-05	0.0011	CbGpPWpGaD
Naproxen—CYP2C9—Biological oxidations—RXRA—thyroid cancer	5.32e-05	0.00109	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TSHR—thyroid cancer	5.28e-05	0.00108	CbGpPWpGaD
Naproxen—Asthenia—Epirubicin—thyroid cancer	5.24e-05	0.000304	CcSEcCtD
Naproxen—AKR1C3—Signaling Pathways—PRKAR1A—thyroid cancer	5.2e-05	0.00107	CbGpPWpGaD
Naproxen—Pruritus—Epirubicin—thyroid cancer	5.17e-05	0.000299	CcSEcCtD
Naproxen—AKR1C3—Disease—CDK1—thyroid cancer	5.11e-05	0.00105	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	5.11e-05	0.00105	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	5.04e-05	0.00104	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—NDUFA13—thyroid cancer	5.02e-05	0.00103	CbGpPWpGaD
Naproxen—Diarrhoea—Epirubicin—thyroid cancer	5e-05	0.00029	CcSEcCtD
Naproxen—Hypersensitivity—Doxorubicin—thyroid cancer	4.98e-05	0.000288	CcSEcCtD
Naproxen—AKR1C3—Signaling Pathways—MEN1—thyroid cancer	4.97e-05	0.00102	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—CCND1—thyroid cancer	4.87e-05	0.001	CbGpPWpGaD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—RXRA—thyroid cancer	4.86e-05	0.000997	CbGpPWpGaD
Naproxen—Asthenia—Doxorubicin—thyroid cancer	4.85e-05	0.000281	CcSEcCtD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	4.83e-05	0.000992	CbGpPWpGaD
Naproxen—Dizziness—Epirubicin—thyroid cancer	4.83e-05	0.00028	CcSEcCtD
Naproxen—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—thyroid cancer	4.83e-05	0.000991	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—MINPP1—thyroid cancer	4.8e-05	0.000986	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—HPGD—thyroid cancer	4.79e-05	0.000983	CbGpPWpGaD
Naproxen—Pruritus—Doxorubicin—thyroid cancer	4.78e-05	0.000277	CcSEcCtD
Naproxen—ALB—Metabolism—MINPP1—thyroid cancer	4.77e-05	0.00098	CbGpPWpGaD
Naproxen—PTGS2—C-MYB transcription factor network—KRAS—thyroid cancer	4.74e-05	0.000973	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—SLC5A5—thyroid cancer	4.73e-05	0.000971	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CHST14—thyroid cancer	4.72e-05	0.000968	CbGpPWpGaD
Naproxen—Vomiting—Epirubicin—thyroid cancer	4.64e-05	0.000269	CcSEcCtD
Naproxen—Diarrhoea—Doxorubicin—thyroid cancer	4.62e-05	0.000268	CcSEcCtD
Naproxen—Rash—Epirubicin—thyroid cancer	4.6e-05	0.000267	CcSEcCtD
Naproxen—Dermatitis—Epirubicin—thyroid cancer	4.6e-05	0.000267	CcSEcCtD
Naproxen—Headache—Epirubicin—thyroid cancer	4.57e-05	0.000265	CcSEcCtD
Naproxen—SLC22A6—Transmembrane transport of small molecules—RXRA—thyroid cancer	4.56e-05	0.000937	CbGpPWpGaD
Naproxen—CYP1A2—Biological oxidations—RXRA—thyroid cancer	4.54e-05	0.000933	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PTCH1—thyroid cancer	4.49e-05	0.000923	CbGpPWpGaD
Naproxen—Dizziness—Doxorubicin—thyroid cancer	4.47e-05	0.000259	CcSEcCtD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	4.43e-05	0.00091	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	4.34e-05	0.000891	CbGpPWpGaD
Naproxen—Nausea—Epirubicin—thyroid cancer	4.34e-05	0.000251	CcSEcCtD
Naproxen—Vomiting—Doxorubicin—thyroid cancer	4.3e-05	0.000249	CcSEcCtD
Naproxen—ALB—Hemostasis—PRKAR1A—thyroid cancer	4.29e-05	0.00088	CbGpPWpGaD
Naproxen—Rash—Doxorubicin—thyroid cancer	4.26e-05	0.000247	CcSEcCtD
Naproxen—Dermatitis—Doxorubicin—thyroid cancer	4.26e-05	0.000247	CcSEcCtD
Naproxen—Headache—Doxorubicin—thyroid cancer	4.23e-05	0.000245	CcSEcCtD
Naproxen—UGT2B7—Metabolism—TPR—thyroid cancer	4.15e-05	0.000853	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—TP53—thyroid cancer	4.13e-05	0.000849	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—SST—thyroid cancer	4.11e-05	0.000844	CbGpPWpGaD
Naproxen—AKR1C3—Disease—NRG1—thyroid cancer	4.1e-05	0.000843	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PRKAR1A—thyroid cancer	4.09e-05	0.000839	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—NDUFA13—thyroid cancer	4.08e-05	0.000838	CbGpPWpGaD
Naproxen—ALB—Metabolism—NDUFA13—thyroid cancer	4.06e-05	0.000833	CbGpPWpGaD
Naproxen—PTGS2—C-MYB transcription factor network—HRAS—thyroid cancer	4.03e-05	0.000827	CbGpPWpGaD
Naproxen—Nausea—Doxorubicin—thyroid cancer	4.01e-05	0.000233	CcSEcCtD
Naproxen—AKR1C3—Metabolism—RXRA—thyroid cancer	3.97e-05	0.000816	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CALCA—thyroid cancer	3.96e-05	0.000812	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—MINPP1—thyroid cancer	3.91e-05	0.000802	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.88e-05	0.000798	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.87e-05	0.000794	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CHST14—thyroid cancer	3.84e-05	0.000788	CbGpPWpGaD
Naproxen—ALB—Metabolism—CHST14—thyroid cancer	3.82e-05	0.000784	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—HPGD—thyroid cancer	3.8e-05	0.000781	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—CP—thyroid cancer	3.77e-05	0.000774	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—TPR—thyroid cancer	3.77e-05	0.000774	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	3.71e-05	0.000762	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	3.69e-05	0.000758	CbGpPWpGaD
Naproxen—AKR1C3—Disease—TERT—thyroid cancer	3.68e-05	0.000757	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—TPR—thyroid cancer	3.62e-05	0.000742	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CDK1—thyroid cancer	3.58e-05	0.000735	CbGpPWpGaD
Naproxen—PTGS2—Disease—TCF7L1—thyroid cancer	3.56e-05	0.000731	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PRKAR1A—thyroid cancer	3.56e-05	0.00073	CbGpPWpGaD
Naproxen—AKR1C3—Disease—HIF1A—thyroid cancer	3.52e-05	0.000724	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—TPR—thyroid cancer	3.37e-05	0.000693	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—MINPP1—thyroid cancer	3.34e-05	0.000686	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—NDUFA13—thyroid cancer	3.32e-05	0.000682	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PRKAR1A—thyroid cancer	3.32e-05	0.000682	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	3.31e-05	0.000681	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.22e-05	0.000662	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—TP53—thyroid cancer	3.21e-05	0.000659	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	3.2e-05	0.000657	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CHST14—thyroid cancer	3.12e-05	0.000641	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—SLC5A5—thyroid cancer	3.11e-05	0.000638	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—HPGD—thyroid cancer	3.09e-05	0.000635	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.08e-05	0.000633	CbGpPWpGaD
Naproxen—ALB—Metabolism—HPGD—thyroid cancer	3.08e-05	0.000632	CbGpPWpGaD
Naproxen—AKR1C3—Disease—BRAF—thyroid cancer	2.92e-05	0.000599	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—NRG1—thyroid cancer	2.87e-05	0.00059	CbGpPWpGaD
Naproxen—ALB—Hemostasis—IFNA2—thyroid cancer	2.84e-05	0.000583	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—NDUFA13—thyroid cancer	2.84e-05	0.000583	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	2.82e-05	0.00058	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—TPR—thyroid cancer	2.75e-05	0.000565	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—SLC5A5—thyroid cancer	2.71e-05	0.000556	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PRKAR1A—thyroid cancer	2.71e-05	0.000556	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CHST14—thyroid cancer	2.67e-05	0.000548	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—RXRA—thyroid cancer	2.61e-05	0.000536	CbGpPWpGaD
Naproxen—PTGS2—Disease—TPR—thyroid cancer	2.61e-05	0.000535	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TERT—thyroid cancer	2.58e-05	0.00053	CbGpPWpGaD
Naproxen—PTGS2—Disease—PRKAR1A—thyroid cancer	2.57e-05	0.000527	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.54e-05	0.000521	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—SLC5A5—thyroid cancer	2.53e-05	0.000519	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—HPGD—thyroid cancer	2.52e-05	0.000517	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PPARG—thyroid cancer	2.51e-05	0.000515	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.51e-05	0.000515	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.49e-05	0.000512	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—HIF1A—thyroid cancer	2.47e-05	0.000507	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	2.46e-05	0.000504	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.45e-05	0.000504	CbGpPWpGaD
Naproxen—PTGS2—Disease—MEN1—thyroid cancer	2.45e-05	0.000503	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—RXRA—thyroid cancer	2.37e-05	0.000487	CbGpPWpGaD
Naproxen—AKR1C3—Disease—PTGS2—thyroid cancer	2.36e-05	0.000484	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—RXRA—thyroid cancer	2.27e-05	0.000467	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.21e-05	0.000454	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—TPR—thyroid cancer	2.18e-05	0.000448	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	2.18e-05	0.000448	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—HPGD—thyroid cancer	2.15e-05	0.000442	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PRKAR1A—thyroid cancer	2.15e-05	0.000441	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—RXRA—thyroid cancer	2.12e-05	0.000436	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—SLC5A5—thyroid cancer	2.06e-05	0.000423	CbGpPWpGaD
Naproxen—AKR1C3—Disease—PTEN—thyroid cancer	2.06e-05	0.000422	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—BRAF—thyroid cancer	2.04e-05	0.00042	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.04e-05	0.000419	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PTGS2—thyroid cancer	1.97e-05	0.000405	CbGpPWpGaD
Naproxen—PTGS2—Disease—CALCA—thyroid cancer	1.95e-05	0.000401	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.95e-05	0.0004	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.93e-05	0.000396	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	1.84e-05	0.000379	CbGpPWpGaD
Naproxen—AKR1C3—Disease—NRAS—thyroid cancer	1.83e-05	0.000377	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—TPR—thyroid cancer	1.78e-05	0.000365	CbGpPWpGaD
Naproxen—PTGS2—Disease—CDK1—thyroid cancer	1.77e-05	0.000363	CbGpPWpGaD
Naproxen—ALB—Metabolism—TPR—thyroid cancer	1.77e-05	0.000363	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PRKAR1A—thyroid cancer	1.75e-05	0.000359	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	1.75e-05	0.000358	CbGpPWpGaD
Naproxen—ALB—Metabolism—PRKAR1A—thyroid cancer	1.74e-05	0.000357	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—RXRA—thyroid cancer	1.73e-05	0.000355	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PTEN—thyroid cancer	1.72e-05	0.000353	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.68e-05	0.000345	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PPARG—thyroid cancer	1.65e-05	0.000339	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—SLC5A5—thyroid cancer	1.63e-05	0.000336	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.58e-05	0.000325	CbGpPWpGaD
Naproxen—AKR1C3—Disease—KRAS—thyroid cancer	1.58e-05	0.000324	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.58e-05	0.000323	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CCND1—thyroid cancer	1.49e-05	0.000306	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—TPR—thyroid cancer	1.45e-05	0.000297	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PTEN—thyroid cancer	1.44e-05	0.000296	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PPARG—thyroid cancer	1.44e-05	0.000295	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	1.42e-05	0.000292	CbGpPWpGaD
Naproxen—PTGS2—Disease—NRG1—thyroid cancer	1.42e-05	0.000291	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—RXRA—thyroid cancer	1.37e-05	0.000282	CbGpPWpGaD
Naproxen—AKR1C3—Disease—HRAS—thyroid cancer	1.34e-05	0.000275	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PPARG—thyroid cancer	1.34e-05	0.000275	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.34e-05	0.000274	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—SLC5A5—thyroid cancer	1.33e-05	0.000273	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	1.33e-05	0.000273	CbGpPWpGaD
Naproxen—ALB—Metabolism—SLC5A5—thyroid cancer	1.32e-05	0.000272	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PTGS2—thyroid cancer	1.3e-05	0.000266	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.29e-05	0.000265	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—NRAS—thyroid cancer	1.28e-05	0.000264	CbGpPWpGaD
Naproxen—PTGS2—Disease—TERT—thyroid cancer	1.27e-05	0.000261	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.25e-05	0.000256	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.24e-05	0.000254	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—TPR—thyroid cancer	1.24e-05	0.000254	CbGpPWpGaD
Naproxen—PTGS2—Disease—HIF1A—thyroid cancer	1.22e-05	0.00025	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	1.22e-05	0.00025	CbGpPWpGaD
Naproxen—AKR1C3—Disease—AKT1—thyroid cancer	1.18e-05	0.000243	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PTEN—thyroid cancer	1.13e-05	0.000232	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PTGS2—thyroid cancer	1.13e-05	0.000232	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—RXRA—thyroid cancer	1.12e-05	0.000229	CbGpPWpGaD
Naproxen—ALB—Metabolism—RXRA—thyroid cancer	1.11e-05	0.000228	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—KRAS—thyroid cancer	1.11e-05	0.000227	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.1e-05	0.000226	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PPARG—thyroid cancer	1.09e-05	0.000224	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.09e-05	0.000223	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—SLC5A5—thyroid cancer	1.08e-05	0.000222	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.08e-05	0.000222	CbGpPWpGaD
Naproxen—ALB—Hemostasis—NRAS—thyroid cancer	1.06e-05	0.000217	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PTGS2—thyroid cancer	1.05e-05	0.000216	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.01e-05	0.000208	CbGpPWpGaD
Naproxen—PTGS2—Disease—BRAF—thyroid cancer	1.01e-05	0.000207	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—AKT1—thyroid cancer	9.92e-06	0.000204	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PTEN—thyroid cancer	9.85e-06	0.000202	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TP53—thyroid cancer	9.82e-06	0.000202	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—HRAS—thyroid cancer	9.4e-06	0.000193	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—SLC5A5—thyroid cancer	9.25e-06	0.00019	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PTEN—thyroid cancer	9.19e-06	0.000189	CbGpPWpGaD
Naproxen—ALB—Hemostasis—KRAS—thyroid cancer	9.12e-06	0.000187	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—RXRA—thyroid cancer	9.09e-06	0.000187	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	8.85e-06	0.000182	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PPARG—thyroid cancer	8.67e-06	0.000178	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	8.67e-06	0.000178	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PTGS2—thyroid cancer	8.59e-06	0.000176	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—AKT1—thyroid cancer	8.3e-06	0.00017	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TP53—thyroid cancer	8.1e-06	0.000166	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—RXRA—thyroid cancer	7.77e-06	0.00016	CbGpPWpGaD
Naproxen—ALB—Hemostasis—HRAS—thyroid cancer	7.75e-06	0.000159	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	7.56e-06	0.000155	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PTEN—thyroid cancer	7.49e-06	0.000154	CbGpPWpGaD
Naproxen—PTGS2—Disease—PTEN—thyroid cancer	7.1e-06	0.000146	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PPARG—thyroid cancer	7.06e-06	0.000145	CbGpPWpGaD
Naproxen—ALB—Metabolism—PPARG—thyroid cancer	7.02e-06	0.000144	CbGpPWpGaD
Naproxen—ALB—Hemostasis—AKT1—thyroid cancer	6.84e-06	0.00014	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—AKT1—thyroid cancer	6.52e-06	0.000134	CbGpPWpGaD
Naproxen—PTGS2—Disease—NRAS—thyroid cancer	6.34e-06	0.00013	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PTEN—thyroid cancer	5.95e-06	0.000122	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PPARG—thyroid cancer	5.74e-06	0.000118	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—AKT1—thyroid cancer	5.68e-06	0.000117	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PTGS2—thyroid cancer	5.55e-06	0.000114	CbGpPWpGaD
Naproxen—ALB—Metabolism—PTGS2—thyroid cancer	5.52e-06	0.000113	CbGpPWpGaD
Naproxen—PTGS2—Disease—KRAS—thyroid cancer	5.45e-06	0.000112	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—AKT1—thyroid cancer	5.3e-06	0.000109	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PPARG—thyroid cancer	4.91e-06	0.000101	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PTEN—thyroid cancer	4.84e-06	9.94e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PTEN—thyroid cancer	4.81e-06	9.88e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—HRAS—thyroid cancer	4.64e-06	9.52e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTGS2—thyroid cancer	4.52e-06	9.28e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—AKT1—thyroid cancer	4.32e-06	8.87e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—AKT1—thyroid cancer	4.09e-06	8.41e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTEN—thyroid cancer	3.94e-06	8.09e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTGS2—thyroid cancer	3.86e-06	7.93e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—AKT1—thyroid cancer	3.43e-06	7.04e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTEN—thyroid cancer	3.37e-06	6.91e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—AKT1—thyroid cancer	2.79e-06	5.73e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—AKT1—thyroid cancer	2.77e-06	5.7e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—AKT1—thyroid cancer	2.27e-06	4.66e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—AKT1—thyroid cancer	1.94e-06	3.98e-05	CbGpPWpGaD
